FAAH and neurodegenerative disease: There is strong preclinical evidence that selective inhibitors of the main AEA-metabolizing enzyme, fatty acid amide hydrolase (FAAH), can ameliorate the unwanted effects in a variety of different laboratory animal models of neurodegenerative diseases (Naidoo et al. 2011; Pertwee 2014).